ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

9:00AM-11:00AM: Abstract Number: 1697

Immune Related Adverse Events from Checkpoint Inhibitor Therapy: Survey of Hospitalists’ Awareness and Experiences

Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1569

Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center

Immunological Complications of Therapy Poster

9:00AM-11:00AM: Abstract Number: 1619

Immunoglobulin G Subclass Ordering Patterns for IgG4-Related Disease at an Academic Medical Center

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1583

Impact of Telehealth Implementation on Practice Patterns and Electronic Health Record Utilization During COVID19

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1685

Impact of the COVID-19 Pandemic Among Children with Rheumatic Diseases from Around the Globe

Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

9:00AM-11:00AM: Abstract Number: 1804

Impact of the Kynurenine/Tryptophan Pathway on Cognitive Dysfunction and Depression in Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1568

Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study

Immunological Complications of Therapy Poster

9:00AM-11:00AM: Abstract Number: 1717

Impact of Treatments on Favorable Outcome over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from a WCE Model in the ESPOIR Cohort

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1718

Impact of Treatments on Radiographic Progression over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1891

Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

9:00AM-11:00AM: Abstract Number: 1712

Implementation of a Musculoskeletal Ultrasound (MSUS) Curriculum in an Academic Rheumatology Fellowship Within an Integrated Health System: A Four-Year Experience

Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1587

Improving Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus in an Internal Medicine Resident Clinic: A Quality Improvement Initiative

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1592

Improving Documentation of Smoking Cessation Counseling Among Spondyloarthropathy Smokers

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1624

Improving Pneumococcal Vaccination in Veterans with Rheumatic Diseases

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1623

Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol

Measures & Measurement of Healthcare Quality Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].